Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016444 · ClinicalTrials.gov registry record
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms
A clinical trial, sponsored by MetroHealth Medical Center.
- Completed
- Registry status
- 311
- Enrollment target
NCT01016444 is a clinical trial that has completed, run by MetroHealth Medical Center. The registered enrollment target is 311 participants.
The verdict
NCT01016444 has completed, sponsored by MetroHealth Medical Center.
- COMPLETED
- Registry status
- 311 participants
- Enrollment target
Study Summary
The hypothesis to be tested is that acutely ill asthmatics who do not resolve their attacks following standard doses of albuterol and require admission to hospital have single nucleotide polymorphisms of their B2 adrenergic receptors that lower B2 agonist responsivity.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-07-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01016444
The ClinicalTrials.gov registry entry for NCT01016444 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 311 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MetroHealth Medical Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01016444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01016444 about?
NCT01016444 is a clinical study titled "Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms". The hypothesis to be tested is that acutely ill asthmatics who do not resolve their attacks following standard doses of albuterol and require admission to hospital have single nucleotide polymorphisms of their B2 adrenergic receptors that lower B2 agonist responsivity.
What is the current status of trial NCT01016444?
This trial is currently completed. The enrollment target is 311 participants. The study started on 2009-12. Estimated completion is 2011-07-29.
Who is sponsoring clinical trial NCT01016444?
This trial is sponsored by MetroHealth Medical Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.